Page 22 - Hal Barron News Today

SOUTHAMPTON researchers are helping to deliver trials of a new therapy which could be used to treat Covid-19.

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection Trial targeted to begin in 1Q:2021 at multiple site...

Vir, GSK In Deal With NHS-Supported AGILE To Evaluate VIR-7832 In Early Treatment Of COVID-19 The trial is due to begin in the first quarter of 2021. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties. These are an enhanced ability to clear infected cells and the potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection. The AGILE trial platform will be the first to test VIR-7832 in hu...

Glaxo Aims to Double Blockbusters in Bid to Revive Portfolio Bloomberg 1/12/2021 Suzi Ring © Bloomberg The GSK company logo is displayed on a sign outside the GlaxoSmithkline Plc Research and Development center in Stevenage, U.K., on Tuesday, Nov. 26, 2019. Glaxo is exploring the trillions of microbes that inhabit the gut in pursuit of novel ways to prevent some of the world’s most common ailments. (Bloomberg) -- GlaxoSmithKline Plc set an ambitious goal of more than doub...

The trial is expected to begin in the first quarter of 2021 across multiple UK sites.

FTSE 100 pharma giant must persuade investors its pipeline has promising drugs as it prepares to spin off its consumer health division

News Category Global Banking & Finance Reviews Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 – Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 – SAN FRANCISCO and LONDON, Dec....

Senior Editor The Food and Drug Administration has given the green light to GlaxoSmithKline for Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus, or SLE, the most common form of lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant. The approval extends the current indication in...

-3.32% gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline GSK, +0.36% said they started dosing patients in a late-stage clinical trial for an experimental antibody-based COVID-19 treatment. The Phase 3 study is part of the National Institutes of Healths Accelerating COVID-19 Therapeutic Interventions and Vaccines Program. The companies are testing VIR-7831 in patients who have been hospitalized due to COVID-19 infections. The investi...

GlaxoSmithKline And Vir Biotechnology Kick Off ACTIV-3 Covid Trial Thu, 17th Dec 2020 21:45 (Alliance News) - GlaxoSmithKline PLC and Vir Biotechnology Inc said Thursday they have started the US National Institutes of Health sponsored ACTIV-3 trial for evaluating VIR-7831 in hospitalised adults with Covid-19. The pair said that the first patient has been dosed in a new sub-trial of the NIHs Accelerating Covid-19 Therapeutic Interventions & Vaccines Program Phase 3 clinical trial. This trial is ...